Cyproheptadine

Generic Name: Cyproheptadine

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₁N

CAS Number: 129-03-3

Unique Ingredient Identifier: 2YHB6175DO

Background: Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome.

Indication: In the US, prescription cyproheptadine is indicated for the treatment of various allergic symptomatologies - including dermatographia, rhinitis, conjunctivitis, and urticaria - as well as adjunctive therapy in the management of anaphylaxis following treatment with epinephrine. In Canada, cyproheptadine is available over-the-counter and is indicated for the treatment of pruritus and for appetite stimulation. In Australia, cyproheptadine is additionally indicated for the treatment vascular headaches.

Cyproheptadine is also used off-label for the treatment of serotonin syndrome.

Associated Conditions: Allergic Reactions caused by Transfusions, Anaphylaxis, Angioedema and urticaria, Cold urticaria, Conjunctivitis allergic caused by Food Allergy, Conjunctivitis allergic caused by inhalant allergens, Perennial Allergic Rhinitis (PAR), Pruritus, Seasonal Allergic Rhinitis, Serotonin Syndrome, Vasomotor Rhinitis, Dermatographism

Associated Therapies: Appetite stimulation

Clinical Trials

The Use of Cyproheptadine in Pediatric Feeding Disorders

Phase 4

Recruiting

Conditions: Pediatric Feeding Disorder, Chronic
Avoidant Restrictive Food Intake Disorder

Interventions: Behavioral: Nutritional Counseling
Drug: Cyproheptadine
Behavioral: Behavioral Counseling

First Posted Date: 2024-12-27

Last Posted Date: 2025-01-16

Lead Sponsor: University of Miami

Target Recruit Count: 50

Registration Number: NCT06751290

Locations: 🇺🇸
University of Miami Department of Pediatric Gastroenterology, Miami, Florida, United States

Pediatric Oncology Nutrition Intervention Trial

Phase 2

Active, not recruiting

Conditions: Nutrition Related Cancer
Malnutrition, Child
Pediatric Cancer
Muscle Loss
Nutrition Aspect of Cancer

Interventions: Dietary Supplement: Oral Nutrition Supplement
Other: Standard of Care
Dietary Supplement: Tube Feed
Drug: Cyproheptadine
Drug: Olanzapine

First Posted Date: 2023-12-18

Last Posted Date: 2025-05-11

Lead Sponsor: Corey Hawes

Target Recruit Count: 19

Registration Number: NCT06175273

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Serotonin Receptor Blockers in Ischemic Mitral Regurgitation

Phase 2

Recruiting

Conditions: Ischemic Mitral Regurgitation

Interventions: Drug: Cyproheptadine 4 Mg Oral Tablet
Other: Placebo

First Posted Date: 2022-07-21

Last Posted Date: 2023-11-15

Lead Sponsor: Laval University

Target Recruit Count: 214

Registration Number: NCT05469165

Locations: 🇨🇦
Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Canada

Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19

Phase 3

Conditions: COVID-19 Pneumonia

Interventions: Drug: Cyproheptadine

First Posted Date: 2021-07-28

Last Posted Date: 2021-08-03

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 274

Registration Number: NCT04979221

Locations: 🇧🇷
Hospital de Clínica de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil

Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19

Phase 2

Conditions: Viral Pneumonia
COVID-19 Pneumonia
Serotonin Syndrome
Platelet Dysfunction

Interventions: Drug: Cyproheptadine Hydrochloride 4 MG

First Posted Date: 2021-05-06

Last Posted Date: 2021-05-06

Lead Sponsor: Ciusss de L'Est de l'Île de Montréal

Target Recruit Count: 60

Registration Number: NCT04876573

Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial

Phase 3

Conditions: Serotonin Syndrome
Viral Pneumonia
Platelet Dysfunction

Interventions: Drug: Cyproheptadine Hydrochloride 4 MG

First Posted Date: 2021-03-29

Last Posted Date: 2021-04-02

Lead Sponsor: Ciusss de L'Est de l'Île de Montréal

Target Recruit Count: 200

Registration Number: NCT04820751

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Phase 2

Recruiting

Conditions: COVID-19

Interventions: Drug: Remdesivir
Drug: Imatinib Mesylate
Drug: Dexamethasone
Biological: dornase alfa
Drug: Celecoxib
Biological: IC14
Biological: narsoplimab
Drug: Cenicriviroc
Drug: Apremilast
Drug: Icatibant
Drug: Cyproheptadine
Drug: Cyclosporine
Drug: Aviptadil
Drug: Famotidine

First Posted Date: 2020-07-27

Last Posted Date: 2024-03-19

Lead Sponsor: QuantumLeap Healthcare Collaborative

Target Recruit Count: 1500

Registration Number: NCT04488081

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Sanford Health, Sioux Falls, South Dakota, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

and more 33 locations

Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects

Phase 2

Completed

Conditions: Alcohol Use Disorder

Interventions: Drug: Cyproheptadine
Drug: Alpress LP

First Posted Date: 2019-09-27

Last Posted Date: 2024-04-15

Lead Sponsor: Kinnov Therapeutics

Target Recruit Count: 154

Registration Number: NCT04108104

Locations: 🇫🇷
Association Hospitalière de Bourgogne Franche-Comté, Saint-Rémy, France
🇫🇷
Cabinet Médical, Bersée, France
🇫🇷
HIA Clermont Tonnerre, Brest, France

and more 32 locations

Noninvasive Markers of Functional Nausea in Children

Not Applicable

Active, not recruiting

Conditions: Nausea

Interventions: Diagnostic Test: Questionnaires
Diagnostic Test: 4 channel electrogastrogram (EGG)
Diagnostic Test: 36 channel high resolution electrogastrogram (HR-EGG)
Diagnostic Test: Magnetogastrogram (MGG)
Diagnostic Test: Electrocardiogram (EKG)
Drug: Ondansetron
Drug: Cyproheptadine Oral Tablet